A tech company that doesn't do R&D or product development has shifted its main business to "buy SOL, stake SOL, and boast about how much SOL we've bought."

In 2025, the total revenue was $7 million, of which $6.8 million came from staking rewards. To put it simply: 97% of the company's income comes from "buy SOL and stake SOL."
Traditional medical device business? It’s barely a blip.
Total assets grew from $7.3 million to $269 million, with $250 million in digital assets—meaning 93% of the company's assets are SOL.
Is this a publicly listed company or a retail whale? Shareholders invested in a medical device company, only to find they’re effectively providing liquidity to Solana. Even more ironically, the company's name is "Sharps Technology"—"Sharp" in the medical device context means "blade" or "surgical knife." Now, the blade is gone, replaced by the "staking yield" scythe.
The management said they plan to "explore more growth paths" in 2026. Most likely, these paths are still: keep buying SOL, keep staking, and keep issuing press releases. Ultimately, this isn’t about betting on technology anymore; it’s about betting that Solana doesn’t fall.